[French ccAFU guidelines - update 2020-2022: retroperitoneal sarcoma]

Area of Science:

• Urological Oncology
• Surgical Pathology
• Medical Imaging

Background:

• Retroperitoneal sarcoma is a rare and aggressive malignancy.
• Optimal management strategies require updated clinical guidelines.

Purpose of the Study:

• To provide updated French urological guidelines for retroperitoneal sarcoma.
• To define best practices for diagnosis, treatment, and follow-up.

Main Methods:

• A comprehensive literature search of Medline (2018-2020) was conducted.
• Evidence levels were evaluated for diagnosis, treatment, and follow-up protocols.
• Guidelines were updated based on current scientific evidence.

Main Results:

• Mandatory CT scans (chest, abdomen, pelvis) for suspected retroperitoneal sarcoma; MRI aids surgical planning.
• Biopsy and registration in a French sarcoma network are required before treatment decisions.
• Surgery is the cornerstone, aiming for negative margins; multidisciplinary team discussion is essential.
• Relapse rates correlate with tumor grade and surgical margins, favoring high-volume centers.

Conclusions:

• Prognosis for retroperitoneal sarcoma is poor, heavily influenced by initial management quality.
• Centralization of care within dedicated sarcoma networks and high-volume centers is imperative.